<DOC>
	<DOCNO>NCT01758510</DOCNO>
	<brief_summary>The purpose study evaluate safety HLA-haplo match Allogenic Bone Marrow Derived stem cell ( `` HYNR-CS-Allo inj '' ) , intrathecal delivery treatment patient amyotrophic lateral sclerosis ( ALS ) . This study open label , dose study use 3+3 design assess safety HLA-haplo match Allogenic Bone Marrow Derived stem cell ( `` HYNR-CS-Allo inj '' )</brief_summary>
	<brief_title>Safety Study HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell Treatment Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description>Amyotrophic lateral sclerosis progressive neurodegenerative disease characterize motor neuron loss . Despite many trial disease-modifying , treatment far change natural course disease . The investigator perform pre-clinical clinical study use autologous bone marrow-derived stem cell ALS . In investigator ' result clinical trial , intrathecal injection autologous bone marrow-derived stem cell safe could slow disease progression might use disease modify strategy patient ALS . In new field , like cell therapy , important issue whether bone marrow derive mesenchymal stem cell use allograft . Many investigator show immunoprivileged immunosuppressive property mesenchymal stem cell result absence major histocompatibility class II antigens secretion T helper type 2 cytokine . One potential advantage allogenic bone marrow derive cell could avoid need procedural delay treatment . And also hypothesize function autologous bone marrow derive cell could impair patient co-morbidities advanced age . This study evaluate safety HYNR-CS-Allo inj ( HLA-haplo match Allogenic bone marrow-derived stem cell ) patient ALS . The patient enrol trial successively allocate three cohort HYNR-CS-Allo inj. , 0.25 X 10^6 cells/kg , 0.5 X 10^6 cells/kg , 1 X 10^6 cells/kg , accord 3+3 , protocol design . The first treatment cohort 0.5 X 106 cells/kg dose cohort . Only maximum six patient give particular dosage . The scheduled assessment visit carry three period : run-in period , treatment period , follow-up period . The run-in period include screen visit write informed consent obtain screening period patient assessed eligibility . It complete within 30 day prior enrollment . The patient meet inclusion criterion start treatment period . During treatment period , subject administer HYNR-CS-Allo inj . 2 time intrathecal administration 28 day interval . The Follow-up period start subject complete treatment period continue final follow-up visit .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Neuromuscular Diseases</mesh_term>
	<mesh_term>Neurodegenerative Diseases</mesh_term>
	<mesh_term>Central Nervous System Diseases</mesh_term>
	<criteria>Patients 25 80 year old Patients sign low motor neuron ( LMN ) upper motor neuron ( UMN ) degeneration clinical , electrophysiological neuropathologic examination Patients diagnose 'Probable ' 'Definite ' ALS accord World Federation Neurology El Escorial criterion Patients whose duration disease within 5 year first diagnosis Patients ALSFRSR score within 21 46 screening Patients visit hospital walk personally protector 's help Patients provide write consent oneself his/her legal representative Patients HLAhaplo match Bone marrow donor Patients n't appropriate diagnostic criterion ALS Patients diagnose primary lateral sclerosis ( PLS ) progressive muscular atrophy ( PMA ) Patients suspected adverse effect stem cell injection ( patient suspect malignant tumor , risk group psychogenic shock , patient serious hypertension ) Patients ALSFRSR score 21 screening Patients perform ventilator tracheostomy screening Patients perform gastrostomy screening Patients unable assess efficacy clinical trial due unattainable Pulmonary Functional Test ( PFT ) patient suspect 40 % less Forced vital capacity ( FVC ) screen Patients find myocardial infarction angina pectoris accord ECG , patient perform Stenting Bypass operation screen Patients take drug clinical trial within past 3 month screen entry Patients epilepsy Patients severe renal dysfunction ( serum creatinine≥2.0mg/dl ) Patients severe liver dysfunction ( ALT , AST , bilirubin≥upper limit normal X 2 ) Pregnant woman , lactate woman , female patient pregnancy plan n't agree adoption contraception method proper medically , male patient n't agree adoption contraception method proper partner participate study Patients hemorrhagic tendency screen Patients virus infection screen Patients know history hypersensitivity/allergy penicillin streptomycin Patients previous stem cell therapy Patients diagnose cancer Patients take drug effect bone marrow function Patients neurological disease except ALS Patients psychotic disease</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>ALS</keyword>
	<keyword>Neurodegenerative disease</keyword>
	<keyword>Motor Neuron Disease</keyword>
	<keyword>Central Nervous System Disease</keyword>
	<keyword>Neuromuscular Disease</keyword>
	<keyword>Bone marrow derive stem cell</keyword>
	<keyword>stem cell therapy</keyword>
	<keyword>intrathecal injection</keyword>
</DOC>